Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2006-11-21
2011-11-15
Mosher, Mary E (Department: 1648)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C435S317100
Reexamination Certificate
active
08057795
ABSTRACT:
We previously reported that NKG2A, a key inhibitory ligand for HLA-E, is expressed on activated TH2, but not TH1, cells. Here we measured cytokine expression in ex vivo TH2 cells and in a mouse model of asthma upon activation with antiCD3/28 and challenge with an NKG2A-specific agonist. We show that signaling through NKG2A modulates Th2 cell effector function. This new molecular pathway data provides a novel explanation and treatment for respiratory virus-associated asthma. RSV and hMPV suppress IFN-γ and HLA-E expression and therefore decrease NKG2A signaling in activated TH2 cells. This results in a relatively robust Th2 response and an unfavorable shift in Th1/Th2 balance. The data presented here suggest that increasing signaling via the NKG2A receptor suppresses Th2 effector function and could positively impact Th1/Th2 balance in asthma.
REFERENCES:
patent: WO 2006/070286 (2006-07-01), None
R & D Systems product Sheet, Monoclonal Anti-human NKG2A Antibody Catalog No. MAB1059, Published Jun. 26, 2007.
Message and Johnston, The immunology of virus infection in asthma, 2001, European Respiratory Journal, vol. 18, pp. 1013-1025.
Freishtat et al., T-Helper 2 Lymphocyte-Expressed NKG2A Suppresses Interleukin-4 Secretion Upon CD3/CD28/HLA-E Costimulation: A Novel Mechanism for T-Helper 2 Dominance in Asthma, 2006, Journal of Investigative Medicine, vol. 54, No. 2, p. S375.
Noyola et al., Human metapneumovirus infections in Mexico: epidemiological and clinical characteristics, 2005, Journal of Medical Micbiology, vol. 54, pp. 969-974.
Freishtat et al., Activated TH2 Lymphocytes Express NKG2A, -C and an NK-Like Phenotype, Mar. 2005, Journal of Investigative Medicine, vol. 53, Supplement No. 3, p. S396, paragraph 52.
Catalog Number: FAB1059A, Monoclonal Anti-Human NKG2A-Allophycocyanin Clone # 131411, Apr. 2005, R&D Systems Product Information Sheet.
Krug and Rabe, Animal Models for Human Asthma: The Perspective of a Clinician, 2008, Current Drug Targets, vol. 9, pp. 438-442.
Gern, Chapter 7: Viral Respiratory Infections in Infancy and Chronic Asthma, 2009, Asthma and Infections, 1stEdition, Editors: Martin and Sutherland, pp. 111-122.
Kawamura, H. et al. Amerlioration of acute graft-versus=host disease by NKG2A Engagement on Donor T Cells, Eur. J. Immunol. 35:2358 (2005).
Brooks, CR et al., Inhibitory Receptor NKG2A Determines Lysis of Vaccinia Virus,-Infected Autologous Targets by NK Cells J. Immunol. 11(2006).
Freishtat, RJ, et al. NKG2A and CD56 Are Expressed on Activated TH2 but not TH1 Lymphocytes, human Immunol. 66:1223 (2005).
Duma, M., et al. NK Cell Receptors Involved in the Response to Human CMV Infection, Curr. Top. Microbiol. Immunol. 298: 20.. (2006).
D'Andrea, et al., “Regulation of T Cell Lymphokine Production by Killer Cell Inhibitory Receptor Recognition of Self HLA Class I Alleles,” The Journal of Experimental Medicine, Aug. 1996, pp. 789-794, vol. 184, The Rockefeller University Press, New York, NY, USA.
Blank Rome LLP
Blumel Benjamin P
Children's Research Institute
Mosher Mary E
LandOfFree
Method of reducing the activation of Th2 lymphocytes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of reducing the activation of Th2 lymphocytes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of reducing the activation of Th2 lymphocytes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4258674